The SEC said Becton Dickinson failed to inform investors about the risks of a flawed infusion pump it manufactured that ...

BD (NYSE: BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system.

Current health news includes scrutiny over Novo's Ozempic drug and its potential link to an eye disease, a campaign against ...

Becton, Dickinson and Co. (BDX) or BD, a New Jersey-based medical device manufacturer, has agreed to pay $175 million to the U.S.

Becton, Dickinson settles with SEC for $175M over misleading investors on software flaws in Alaris pumps. Read more here.

The SEC reached a settlement with Becton Dickinson over allegations of misleading investors regarding risks tied to its Alaris infusion pump. The company agreed to a $175 million civil penalty without ...

The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. (BD) ...

The newest piece of equipment in the Diagnostic Imaging department of Estes Park Health was purchased through the generous ...

According to a new comprehensive report from The Insight Partners, global patient controlled injectors market is expected to ...